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Abstract In the present study of 9,000 individuals
representative of the general population, we have
considered whether the addition of common single
nucleotide polymorphisms (SNPs) in the promoter region
of Apolipoprotein E (APOE) improve the statistical
explanation of variation in lipid traits and test the
hypothesis that the estimated genotype effects are inde-
pendent of factors indexed by gender and age. To address
these questions, we have asked, for each gender and for
each 20-year age strata (young: 20–39 years; middle-aged:
40–59 years; old: 60–79 years; very old: 80–100 years),
how much trait variation is associated with the traditional
ε2, ε3, and ε4 allelic variations defined by the
g.2059T→C and g.2197C→T SNPs in the fourth exon
of the APOE gene, and how much additional trait variation
is associated with genotypes defined by combining the
g.2059T→C and g.2197C→T SNPs with one, two, or
three promoter SNPs. Our study demonstrates that the
pleiotropic effects of genotype variation defined by the
traditional ε2, ε3, and ε4 alleles on five plasma measures
of lipid metabolism manifest differently in women and
men and change significantly during the life cycle for
high-density lipoprotein cholesterol in women. Multi-site
genotypes defined by adding SNPs located in the 5′
promoter region to the traditional g.2059T→C and
g.2197C→T SNPs doubled the estimate of genetic
variance of high-density lipoprotein and apolipoprotein
Al in middle-aged females.
Introduction
The apolipoprotein E (APOE) protein plays a pivotal role
in lipid metabolism and exerts its biological function as a
surface component of triglyceride-rich lipoprotein parti-
cles. These include chylomicrons, chylomicron remnants,
very-low-density lipoproteins (VLDLs), intermediate-den-
sity lipoproteins (IDLs), and a subclass of high-density
lipoprotein cholesterol (HDL-C) particles (Weisgraber
1994). The protein serves as a ligand for the low-density
lipoprotein (LDL) receptor and the LDL receptor-related
protein (LRP). It is responsible for a large fraction of the
clearance of triglycerides (TG) and total cholesterol (TC)
from the plasma compartment (Havel and Kane 2001). In
humans, three major isoforms of APOE are present,
APOE-2, APOE-3, and APOE-4 (Utermann et al. 1977).
Differences are defined by cysteine–arginine interchanges
at positions 112 and 158 in the 299-amino-acid APOE
chain (Weisgraber 1994). Two variable sites, located in
exon 4 of the APOE gene (positions g.2059T→C and
g.2197C→T, Fig. 1, corresponding to Single nucleotide
polymorphisms (SNPs) 3937 and 4075 in reference
sequence AF261279) are responsible for these two
amino acid changes. The SNPs at each site combine to
determine three alleles (ε2, ε3, and ε4) and six common
APOE genotypes (ε22, ε32, ε42, ε33, ε43, and ε44). In
most populations, a stepwise increase in TC is associated
with allelic changes from ε2 to ε3 to ε4 (Davignon et al.
1988; Mahley and Rall 2001). Carriers of the ε4 allele are
at increased risk for cardiovascular disease (CVD) and
Alzheimer’s disease (Corder et al. 1993; Strittmatter et al.
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1993; Tiret et al. 1994; Wilson et al. 1994; Stengård et al.
1995; Frikke-Schmidt et al. 2000b, 2001).
In the population at large, the six common APOE
genotypes statistically explain 2%–5% and 11%–20% of
the interindividual variation in TC and plasma APOE,
respectively (Frikke-Schmidt et al. 2000a; Stengård et al.
2002). The fraction of interindividual phenotypic variabil-
ity in TC and APOE statistically explained by the six
common APOE genotypes is greater in females than in
males (Frikke-Schmidt et al. 2000a; Stengård et al. 2002;
Kaprio et al. 1991; Xhignesse et al. 1991; Kamboh et al.
1993; Heng et al. 1995; Zaman et al. 1997; Kamboh et al.
1999). The statistical correlation between measures of
lipid metabolism among individuals with the same gen-
otype differs between genders (Reilly et al. 1994).
Interindividual trait variability associated with the com-
mon APOE genotypes and the correlations between traits
within genotype classes also change as a function of age
(Zerba and Sing 1993; Zerba et al. 1996, 2000). These
findings suggest that statistical adjustment, for gender and
age variation, of the quantitative traits that connect
genome variation with variation in the risk of CVD
(before making inferences about the impact of common
genetic variations that influence measures of CVD risk) is
not consistent with the biological reality of the natural
history of CVD (Barrett-Connor et al. 1984; Hayward et
al. 2000). Our study considers the impact of the genetic
and environmental contexts indexed by gender and age on
the contribution of the common “public” variations in the
APOE gene to statistically explaining variation in mea-
sures of lipid metabolism.
Any strategy for evaluating the contribution of the
APOE gene must consider the plethora of DNA sequence
variation revealed by resequencing (Nickerson et al.
2000). Stengård et al. (2002) have compared the gender-
and population-specific fraction of interindividual trait
variability statistically explained by the common geno-
types defined by the ε2, ε3, and ε4 alleles coded by the
g.2059T→C and g.2197C→T SNPs with variability
statistically explained by genotypes defined by consider-
ing one or more additional SNPs. Their study involves
SNPs identified by resequencing 5.5 kb of the APOE gene
Fig. 1 Relative frequency of
the least frequent allele at each
of the five variable sites for each
of four age categories separately
for females and males
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in samples of 24 individuals from each of three
populations. Twenty-two variable sites have been detected
(21 SNPs and one multi-allelic insertion/deletion poly-
morphism; Nickerson et al. 2000). Ten of the 21 SNPs
vary in all three populations. This subset of “public” SNPs
includes the g.2059T→C and g.2197C→T SNPs and three
SNPs (g.−1318A→T, g.−1254T→C, and g.−1046G→T,
Fig. 1, corresponding to SNPs 560, 624, and 832 in
reference sequence AF261279) located in the 5′ promoter
region of the APOE gene (Fullerton et al. 2000). Stengård
et al. (2002) have demonstrated, in samples of individuals
aged 45–64, that these three promoter SNPs improve the
statistical explanation of variation in measures of lipid
metabolism in a gender- and population-specific manner
when included with the g.2059T→C and g.2197C→T
SNPs in the definition of APOE genotypes. In the present
study, we test the five common APOE SNPs in a very
large data set, because validation in the population at large
is of critical value in judging the relevance of genetic
variation. We have asked, for each gender and for each 20-
year age strata (young: 20–39 years; middle-aged: 40–
59 years; old: 60–79 years; very old: 80–100 years) how
much trait variation is associated with genotype variation
defined by the g.2059T→C and g.2197C→T SNPs, and
how much additional trait variation is associated with
genotypes defined by combining the g.2059T→C and
g.2197C→T SNPs with one, two, or three of the three
promoter SNPs. Finally, we have asked whether there is
statistically significant heterogeneity in the influence of
APOE genotype effects among age strata for each lipid
trait in each gender.
Materials and methods
Sample
We studied individuals who participated in the third
examination of The Copenhagen City Heart Study from
1991 to 1994. The primary sample of 19,698 men and
women was randomly drawn in January 1976 from the
Copenhagen Population Register by using the special
Central Personal Register Code, which includes date of
birth and a registration number (Schnohr et al. 2001). The
sample was drawn from a population of approximately
90,000 inhabitants 20 years and older living within ten
wards surrounding the Rigshospitalet, The National
University Hospital of Copenhagen. At the second exam-
ination (1981–1983), the population-based sample was
supplemented with a new sample of 500 men and women
of 20–24 years of age. At the third examination (1991–
1994), the study sample was supplemented with 3,000
men and women aged 20–49, stratified into six 5-year age
groups of 250 females and 250 males. Of the 16,563
individuals invited to the third examination, 10,135
participated, 9,259 gave blood, and 9,203 were genotyped
for this study. Details on selection, invitation, and
examination procedures are described in Schnohr et al.
(2001). When individuals with missing trait values or trait
values that exceeded five standard deviations from the
overall gender sample means were excluded, 9,011
individuals (55% women) remained for the present
study. For each gender, we subdivided this sample into
four 20-year age strata (young: 20–39 years; middle-aged:
40–59 years; old: 60–79 years; very old: 80–100 years).
All participants gave informed consent, and the study was
approved by the Danish Ethics Committee for Copenha-
gen and Frederiksberg (no. 100.2039/91).
Laboratory analyses
TC, apolipoprotein B (APOB), HDL-C, apolipoprotein Al
(APOAI), and TG (Boehringer Mannheim, Mannheim,
Germany) were measured in non-fasting plasma. Typical
day-to-day coefficients of variation were 3.0, 3.9, 2.5, 5.4
and 3.5% for TC (at the level of 3.9 mmol/l), APOB (at the
level of 87 mg/dl), HDL-C (at the level of 1.0 mmol/l),
APOAI (at the level of 155 mg/dl), and TG (at the level of
1.5 mmol/l), respectively. No seasonal variation in lipids,
lipoproteins, and apolipoproteins was detectable. Geno-
types of the common APOE polymorphism were deter-
mined by polymerase chain reaction (PCR) followed by
digestion with HhaI as described (Hixson and Vernier
1990), with a slight modification (Frikke-Schmidt et al.
2000a). Genotypes of the three SNPs in the APOE
promoter region (g.−1318A→T, g.−1254T→C, and g.
−1046G→T, Fig. 1) were determined in a nested PCR
design. First, a 952-bp fragment of the promoter was
amplified (forward primer: 5′TGCTCAAGGTCACAAC-
CAAA, reverse primer: 5′CAGGGTCCCAGCTCTTTC-
TA). The PCR product (5 μl) was diluted 1:20, and the rest
was digested with AluI, which recognized bases at the g.
−1254T→C site (corresponding to site 427; Bullido et al.
1998), and produced fragments that clearly distinguished
the CC, TC, and TT variants. Second, the diluted PCR
product was used as the template for a second PCR
amplifying two fragments spanning the g.−1318A→T and
g.−1046G→T sites (corresponding to sites 491 and 219,
respectively; Bullido et al. 1998). The following primers
were used: site g.−1318A→T, forward primer: 5′
TGTTGGCCAGGCTGGTCTCGA, reverse primer: 5′
GCTGGGGGCGGTAGCTCAC; site g.−1046G→T, for-
ward primer: 5′CCTACTTTCTTTCTGGGATCCAGG,
reverse primer: 5′GAGGACACCTCGCCCAGTGAT. We
designed two mismatches (underlined nucleotides) to
create restriction sites for DpnII at sites g.−1318A→T
and g.−1046G→T. This digestion resulted in unique
fragment lengths for each genotype at site g.−1318A→T
(AA, AT, TT) and site g.−1046G→T (GG, GT, TT). To
avoid preferential amplification of the largest fragment
possible, between forward primer site g.−1318A→T and
reverse primer site g.−1046G→T, we down-titrated the
concentrations of these oligonucleotides to 1:30 and 1:20
of their corresponding primers. To eliminate a potential
misclassification among AT and TT at site g.−1318A→T
(most likely because of incomplete digestion), we
performed a control assay for the subset of AT and TT
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individuals. The diluted 952-bp PCR product was used as
the template, and the following primers were designed:
forward primer: 5′TGTTGGCCAGGCTGGTTTTAA, re-
verse primer: 5′CTCCTTTCCTGACCCTGTCC (under-
lined nucleotides indicate mismatches that create a
restriction site for DraI at site g.−1318A→T). This latter
control assay resolved a minor misclassification between
AT and TT individuals in the DpnII assay and was
modified according to a method previously described by
Artiga et al. (1998).
Statistical analyses
Distributions of plasma TG were positively skewed in
both genders. The application of the natural logarithm (ln)
transformation decreased the skewness to less than 0.5 in
each gender. To test whether variances of TC, APOB,
HDL-C, APOAI, and ln TG differed between genders for
each age strata we used the Fisher’s F-ratio (Sokal and
Rohlf 1995). To test whether trait means differed between
genders for each age strata, Student’s t-test was applied
when the Fisher’s F-ratio test did not show significant
heterogeneity of the gender variances. When heterogeneity
of variances was present, Student’s t-test with the
Satterthwaite’s correction was used. Chi-square statistics
were used to test homogeneity of relative allele and
genotype frequencies across age strata in each gender.
The Boerwinkle and Sing (1986) biased corrected
estimator of genetic variance (σG
2) in the population
sample was used to estimate the interindividual phenotypic
variability associated with genotype variation defined by
different combinations of the five SNPs. This estimate
summarizes deviations of the genotype means from the
grand mean, weighted by their relative frequencies. This
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where n is the total sample size, k is the number of
genotypes, Y is the sample grand mean, ni is the number of
individuals with the ith genotype, Yi is the mean of the ith
genotype, Yij is the phenotype of the jth individual in the
ith genotype class and MSW is the mean squared estimate
of the phenotypic variability among individuals within
genotype classes.
We used permutation methods (Fischer 1935; Churchill
and Doerge 1994; Good 2000) to test whether the six
genotypes defined by the g.2059T→C and g.2197C→T
SNPs contributed significantly to σG
2 (Ho: σG
2=0) in each
gender-age group strata, to test whether the addition of one
or more of the three promoter SNPs significantly increased
σG
2 in each gender-age strata, and to test whether
estimates of σG
2 differed significantly across age groups
within each gender.
We constructed a test of the null hypothesis, σG
2=0, by
randomly shuffling the phenotypes of each trait among the
individuals 1,000 times and by calculating an estimate of
σG
2 for each permuted sample. The 1,000 values of SG
2
formed a null distribution of variance estimates. The null
hypothesis was rejected if the original estimate of SG
2
from the non-permuted sample exceeded the value of SG
2
associated with the upper α-percentage of the null
distribution of values obtained from the 1,000 permuta-
tions (Churchill and Doerge 1994).
To evaluate if the addition of one or more of the three
promoter SNPs improved the prediction of variability in
measures of lipid metabolism, we randomly shuffled the
observed phenotypes among genotypic classes within each
of the six genotypes classes defined by g.2059T→C and
g.2197C→T 1,000 times and calculated the difference, Vd,
between SG
2 for genotypes defined by g.2059T→C and
g.2197C→T and SG
2 for genotypes defined by these two
sites and one or more promoter SNPs. The null hypothesis
of no improvement in prediction was rejected if the
original value of Vd obtained from the non-permuted
sample exceeded the value of Vd associated with the upper
α-percentage of the distribution of values obtained from
the 1,000 permutations (Stengård et al. 2002).
To test whether the genetic variability, explained by
genotypes defined by a particular combination of SNPs,
differed significantly as a function of age for each gender
(Ho: σG
2 constant in all age strata), we carried out the
following. First, we calculated a measure of the deviations
of genetic variances estimated for the four age groups from







whereS2Gi is the estimate of genetic variance for the ith
age category andS2Gpooled is the genetic variance when all
age groups are pooled. Second, we randomly shuffled the
four age group identifiers among individuals and recalcu-






The 1,000 values of λ permuted, obtained from the 1,000
permutations of the age group assignment, generated a null
distribution. The null hypothesis was rejected if the
λobserved (non-permuted data) exceeded the upper α-
percentage of the values in the null distribution.
Pairwise linkage disequilibrium (LD) was measured
with the LD parameter D, calculated as D=Pij−pipj, where
Pij is the frequency of the most common gametic type for a
pair of sites, and pi and pj are the frequencies of the
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nucleotides in that haplotype (Hartl and Clark 1997). The
r2 measure of LD was also considered (Pritchard and
Przeqorsku 2001). Significance levels for pairwise linkage
were evaluated by χ2 statistics.
Unless otherwise denoted, we considered an α-level of
0.05 as the criterion for statistical significance.
Results
Age- and gender-specific distributions of the relative
allele frequencies
The relative frequency of the least common allele at a
variable site ranged from 0.06 to 0.49 (Fig. 1). Relative
frequencies at four (SNPs at positions g.−1318A→T, g.
−1254T→C, g.2059T→C, and g.2197C→T) of the five
variable sites ranged from 0.06 to 0.17, whereas the minor
allele was more common (0.46–0.49) in all age and gender
strata at the fifth site (SNP at position g.−1046G→T).
There was no statistically significant evidence of hetero-
geneity of relative allele frequencies across age strata in
either gender for any of the five SNPs. The largest
difference between age strata was observed for site
g.2059T→C. The relative frequency of the minor allele
ranges from 0.138 (very old) to 0.170 (old) in females and
from 0.139 (very old) to 0.166 (old) in males. When very
old individuals were compared with the other three pooled
age strata, the very old individuals have a marginally
significantly decreased relative frequency of the minor
allele at site g.2059T→C in females (P=0.08), but not
males (P=0.23). The relative allele frequencies of alleles at
each of the five SNPs were not significantly different from
those reported by Stengård et al. (2002) for the Rochester,
Minn., USA population. Four of the five SNPs
(g.2059T→C, g.−1046G→T, g.−1254T→C, g.
−1318A→T) had relative allele frequencies that were
significantly different from those estimated for the Jack-
son, Minn., USA population (Stengård et al. 2002) and
three of the five (g.2197C→T, g.2059T→C, g.
−1254T→C) had relative allele frequencies that were
significantly different from those estimated for the pop-
ulation of North Karelia, Finland (Stengård et al. 2002).
The relative allele frequencies of the three 5′ SNPs were
not different in demented participants vs. non-demented
participants in a subsample of the cohort screened for
dementia (participants above the age of 65). As expected,
the ε4 allele was associated with dementia, as shown
previously in the Copenhagen City Heart Study (Frikke-
Schmidt et al. 2001).
Gender- and age-specific distributions of quantitative
measures of lipid metabolism
Phenotypic characteristics are summarized in Table 1 for
each of the eight gender-age group samples. Although
only a difference of one year, the average age of females
was significantly greater than males in the sample of old
individuals. Except for TC in the middle-aged sample and
lnTG in the very old sample, average levels of each of the
five quantitative measures of lipid metabolism were
significantly different between genders within each of
the four age strata. On average, females had lower TC and
APOB levels than males in the young group and higher
levels than males in the old and very old groups. Females
had higher average HDL-C and APOAI levels in all age
groups and lower average lnTG in all but the very old age
group. Interindividual variability of at least two of five
lipid traits was significantly different between genders
within each of the age strata.
Significant heterogeneity of the average level of each of
the five measures of lipid metabolism across age strata was
observed in males and for all but HDL-C in females.
Significant heterogeneity of the phenotypic variance
across age strata was observed for each of the five lipid
traits in both genders, with the exception of TC in males.
The average level and variance of each lipid trait was
smallest in the young group and tended to larger values in
the older age groups. Heterogeneity of the distribution of
lipid traits among gender and age strata documented the
importance of evaluating the age and gender influence on
the relative role of genetic variation and justified the
stratified analyses presented here.
Gender- and age-specific association of interindividual
variation in measures of lipid metabolism with
genotypes defined by the ε2, ε3, and ε4 alleles
The contribution of the six common genotypes defined by
variable sites g.2059T→C and g.2197C→T to explaining
interindividual variation in TC and APOB was statistically
significant in both genders in each age group (Table 2).
The percentage of phenotypic variation statistically
explained was greater in females (TC ranged from 3.8%
to 4.7%; APOB ranged from 7.4% to 10.6%) than males
(TC ranged from 1.1% to 5.0%; APOB ranged from 4.5%
to 6.4%) in each of the four age groups. Except for HDL-C
in the old, the variation of HDL-C and APOAI associated
with the six common genotypes was statistically signifi-
cant in all age strata in females (HDL-C ranged from 0.1%
in the old group to 6.5% in the very old; APOAI ranged
from 0.1% in the old to 3.5% in the very old). In males,
these six genotypes explained a small, but significant,
amount of APOAI variation in the middle-aged (0.4%) and
old (0.7%) groups, and HDL-C variation in the old age
group (0.4%). The percentage of variance of lnTG
statistically explained ranged from 0.2 to 2.5 in females
and from 0.0 to 0.7 in males and was significant only in
old and very old females, and in middle-aged and old
males.
In females, but not males, there was statistically
significant evidence of heterogeneity across age strata
for the estimates of the genetic variance of HDL-C
associated with variation in the six common genotypes
(from 0.6 in old to 22.3 in very old, P=0.015). There was
no statistically significant evidence of heterogeneity of the
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Table 1 Phenotypic character-
istics of females and males from
the population at large in age
strata of 20 years
Variable Females (n=745) Males (n=683) P-values





Age (years) 32 24 32 24 0.69 0.93
Plasma measure
TC (mg/dl) 194 1,370 203 1,754 <0.0001 0.001
APOB (mg/dl) 65 311 74 371 <0.0001 0.02
HDL-C (mg/dl) 66 236 51 169 <0.0001 <0.0001
APOAl (mg/dl) 143 599 123 451 <0.0001 <0.0001
lnTG (mg/dl) 4.55 0.22 4.87 0.30 <0.0001 <0.0001
Variable Females (n=1,581) Males (n=1,449) P-values





Age (years) 51 33 51 31 0.95 0.13
Plasma measure
TC (mg/dl) 235 2,130 235 1,932 0.84 0.06
APOB (mg/dl) 83 502 89 466 <0.0001 0.15
HDL-C (mg/dl) 66 343 53 261 <0.0001 <0.0001
APOAl (mg/dl) 149 758 131 610 <0.0001 <0.0001
lnTG (mg/dl) 4.81 0.25 5.09 0.33 <0.0001 <0.0001
Variable Females (n=2,396) Males (n=1,752) P-values





Age (years) 69 27 68 29 0.008 0.07
Plasma measure
TC (mg/dl) 261 2,133 236 1,845 <0.0001 0.001
APOB (mg/dl) 94 481 90 452 <0.0001 0.16
HDL-C (mg/dl) 67 381 54 279 <0.0001 <0.0001
APOAl (mg/dl) 154 811 132 616 <0.0001 <0.0001
lnTG (mg/dl) 4.99 0.21 5.08 0.27 <0.0001 <0.0001
Variable Females (n=225) Males (n=180) P-values




Very old, age 80–100
Age (years) 83 6 83 6 0.59 0.54
Plasma measure
TC (mg/dl) 263 2,538 229 1,801 <0.0001 0.02
APOB (mg/dl) 95 477 87 432 0.0004 0.49
HDL-C (mg/dl) 66 345 55 264 <0.0001 0.06
APOAl (mg/dl) 151 716 130 616 <0.0001 0.29
lnTG (mg/dl) 5.02 0.19 4.97 0.23 0.30 0.16
Variable P-values F-test P-values F-test
Mean Variance Mean Variance
TC (mg/dl) <0.0001 <0.0001 <0.0001 0.5051
APOB (mg/dl) <0.0001 <0.0001 <0.0001 0.006
HDL-C (mg/dl) 0.2518 <0.0001 0.0006 <0.0001
APOAl (mg/dl) <0.0001 <0.0001 <0.0001 <0.0001
lnTG (mg/dl) <0.0001 0.0002 <0.0001 <0.0001
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estimate of genetic variance among age strata for the other
four traits in either gender.
Gender- and age-specific contributions of one
additional APOE promoter SNP to the statistical
explanation of variation in measures of lipid
metabolism
The gender- and age-specific estimates of the genetic
variance statistically explained by the six genotypes
defined by the g.2059T→C and g.2197C→T SNPs and
the three SNP genotypes defined by including one
additional promoter SNP are presented for each trait in
the left panel of Fig. 2. In young, old, and very old
females, none of the combinations of three SNP genotypes
statistically explained significantly more genetic variance
in any of the five lipid traits than did the six common
genotypes defined by the g.2059T→C and g.2197C→T
SNPs. In middle-aged females (40–59 years), all three
combinations of three SNP genotypes significantly
improved the prediction of genetic variance in HDL-C
and APOAI. The largest increase in the genetic variance of
HDL-C was associated with the genotypes defined by
combining the SNP at position g.−1046G→T with the
g.2059T→C and g.2197C→T SNPs, from 2.9 to 6.2
(P≤0.01). When combined with g.2059T→C and
g.2197C→T to define three SNP genotypes, SNP g.
−1254T→C gave the largest increase in the genetic
variance of APOAI, from 7.1 to 12.7 (P≤0.05).
In young males, two different combinations of three
SNP genotypes significantly increased the explanation of
trait variation. Adding the SNP at g.−1046G→T sig-
nificantly increased the genetic variance of TC and APOB
(from 62.4 to 100.5 and from 22.0 to 25.9, P≤0.01,
P≤0.05, respectively). The SNP at position g.−1254T→C
significantly increased the estimate of genetic variance of
APOAI from 0.0 to 5.2 (P≤0.05). In old males, the SNP at
position g.−1318A→T significantly increased the estimate
of the genetic variance of APOAI from 4.2 to 9.3
(P≤0.01).
Gender- and age-specific contributions of the four and
five SNP combinations to the statistical explanation of
variation in measures of lipid metabolism
The gender- and age-specific estimates of amount of
variation statistically explained by genotypes defined by
combining the g.2059T→C and g.2197C→T SNPs with
two or three additional promoter SNPs are presented for
each trait in the right panel of Fig. 2. In females, none of
the four or five SNP combinations predicted significant
additional variability in any of the lipid traits beyond that
predicted by the best three-site combination. In young,
middle-aged, and very old males, none of the four or five
SNP combinations defined genotypes that predicted
significant additional genetic variance in any lipid trait
beyond that predicted by the best three-site. In old males,
one four-site combination (SNPs g.−1254T→C, g.
−1046G→T, g.2059T→C, and g.2197C→T) defined
genotypes that significantly explained more genetic vari-
ability in lnTG when compared with the genotypes defined
by the best three-site combination (SNPs g.−1254T→C,
g.2059T→C, and g.2197C→T; 0.005 vs. 0.003, P≤0.038).
Of the 48 ɛ22 individuals, only two developed overt
type III hyperlipoproteinemia with increased levels of both
TG (6.27 and 5.44 mmol/l) and TC (11.8 and 11.2 mmol/
l). Neither SNPs g.−1318A→T, g.−1254T→C, or g.
−1046G→T, nor any combination thereof was selectively
clustered in the two (ε22) type III hyperlipoproteinemic
individuals.
Pairwise LD in the APOE gene
The LD structure for the five common variable sites in
APOE is given in Table 3 for females pooled and males
pooled. In general, the age-stratified pairwise LDs
Table 2 Estimates of genetic variance (σG
2) and percentage
phenotypic variance associated with genotypes defined by the ε2,
ε3, and ε4 APOE alleles coded by the g.2059T→C and g.2197C→T
SNPs for each gender and age strata of 20 years. Six genotypes were
observed in all gender and age strata samples except for the very old
males. In the very old male age-group, only five genotypes were









TC (mg/dl) 55.6*** 4.1 62.4*** 3.6
APOB (mg/dl) 25.1*** 8.1 22.0*** 5.9
HDL-C (mg/dl)a 6.3*** 2.7 0.0 0.0
APOAl (mg/dl) 7.7* 1.3 0.0 0.0
lnTG (mg/dl) 0.001 0.6 0.0 0.1
Middle-aged, age 40–59
TC (mg/dl) 87.1*** 4.1 22.2*** 1.1
APOB (mg/dl) 37.1*** 7.4 20.8*** 4.5
HDL-C (mg/dl) 2.9** 0.8 0.0 0.0
APOAl (mg/dl) 7.1*** 0.9 2.5* 0.4
lnTG (mg/dl) 0.001 0.3 0.002* 0.6
Old, age 60–79
TC (mg/dl) 101.1*** 4.7 56.3*** 3.1
APOB (mg/dl) 44.2*** 9.2 28.9*** 6.4
HDL-C (mg/dl) 0.6 0.1 1.1* 0.4
APOAl (mg/dl) 3.8*** 0.5 4.2*** 0.7
lnTG (mg/dl) 0.001* 0.2 0.002** 0.7
Very old, age 80–100
TC (mg/dl) 96.0* 3.8 89.3* 5.0
APOB (mg/dl) 50.4*** 10.6 20.2* 4.7
HDL-C (mg/dl) 22.3** 6.5 0.0 0.0
APOAl (mg/dl) 24.8* 3.5 1.8 0.3
lnTG (mg/dl) 0.005* 2.5 0.0 0.0
Significant at *α≤ 0.05, **α≤ 0.01, ***α≤ 0.001
aSignificant heterogeneity across age strata in females (P=0.015)
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Fig. 2a–e The gender- and age-
specific estimates of the genetic
variance for the genotypes de-
fined by the g.2059T→C and
g.2197C→T SNPs and for each
possible combination of one or
more additional promoter SNPs





**P≤0.01, ***P≤0.001 for the
genotypes defined by the
g.2059T→C and g.2197C→T
SNPs. +P≤0.05, ++P≤0.01 for
the genotypes defined by com-
binations of three sites that
improved the prediction in trait
variability beyond that ex-
plained by the genotypes de-
fined by the g.2059T→C and
g.2197C→T SNPs. † P≤0.05,
†† P≤0.01 for the four and five
site combinations that improved
the explanation of trait variabil-
ity beyond that explained by
genotypes defined by
g.2059T→C and g.2197C→T
SNPs. ‡ P≤0.05 for the four and
five site combinations that im-
proved the explanation of trait
variability beyond that ex-
plained by genotypes defined by
the best three site combination
Table 3 Pairwise LDs. D=Pij-
pipj; r
2 is the correlation coeffi-
cient for alleles at site 1 and site
2. The χ2 statistic was used to
test significance of r2
Site 1/site 2 Females Males
D r2 P-values D r2 P-values
g.−1318A→T/g.−1254T→C −0.013 0.014 <0.0001 −0.013 0.014 <0.0001
g.−1318A→T/g.−1046G→T 0.005 0.001 0.050 0.005 0.001 0.074
g.−1318A→T/g.2059T→C −0.025 0.034 <0.0001 −0.024 0.033 <0.0001
g.−1318A→T/g.2197C→T 0.015 0.023 <0.0001 0.015 0.023 <0.0001
g.−1254T→C/g.−1046G→T −0.008 0.002 <0.0001 −0.009 0.004 <0.0001
g.−1254T→C/g.2059T→C −0.004 0.001 0.022 −0.001 0.000 0.592
g.−1254T→C/g.2197C→T 0.024 0.077 <0.0001 0.021 0.062 <0.0001
g.−1046G→T/g.2059T→C 0.045 0.058 <0.0001 0.038 0.044 <0.0001
g.−1046G→T/g.2197C→T 0.039 0.079 <0.0001 0.037 0.073 <0.0001
g.2059T→C/g.2197C→T −0.014 0.018 <0.0001 −0.013 0.017 <0.0001
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resembled the pooled estimates for both females and
males, with the exception of the very old male group. All
LDs involving the g.2197C→T SNP, which defines the ε2
allele, were markedly different in this group, most likely
because of the absence of the rare ε22 genotype among
these very old males. The three pairs with strongest
correlation in both females and males were g.−1254T→C
vs. g.2197C→T, g.−1046G→T vs. g.2059T→C, and g.
−1046G→T vs. g.2197C→T (r2 0.044–0.079, P<0.0001
for all comparisons).
Discussion
We observed pleiotropic effects of the traditional ε2, ε3
and ε4 APOE polymorphism, defined by the g.2059T→C
and g.2197C→T SNPs, on five plasma measures of lipid
metabolism. The explained variance was greatest for TC
and APOB and smallest for HDL, APOAI, and TG in all
age-gender strata. The traditional APOE genotypes
explained more phenotypic variance in females than in
males in all lipid traits, except TG. Only the genetic
variance of HDL-C explained by the six traditional APOE
genotypes differed significantly across age groups, and
this was observed in females only. In no case did we
observe an improvement in prediction associated with
adding a 5′ SNP that was consistent across age or gender
Fig. 2a–e (continued)
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strata. Multi-site genotypes defined by adding SNPs
located in the 5′ promoter region to the traditional
g.2059T→C and g.2197C→T SNPs doubled the estimate
of genetic variance of HDL and APOAI in middle-aged
females. Adding 5′ SNPs increased the genetic variance of
TC, APOB, and APOAI in young and old males.
Pleiotropic, age-, and gender-dependent effects of
genotypes defined by the ε2, ε3, and ε4 alleles on
variation in measures of lipid metabolism
Over the last two decades, numerous studies have
documented pleiotropic effects of the APOE gene on
interindividual variation in TC, APOB, APOE, and TG
(Hallman et al. 1991; Kaprio et al. 1991; Reilly et al. 1991;
Sing and Davignon 1985; Xhignesse et al. 1991). Our
population-based study is the largest to date to document
these pleiotropic effects. In particular, we have confirmed
a significant influence of the genotypes defined by the ε2,
ε3, and ε4 alleles on additional lipid traits, such as HDL-C
and APOAI (Frikke-Schmidt et al. 2000a).
Age and gender index a broad spectrum of physiolog-
ical and environmental conditions that the individual
experiences through life (Barrett-Connor et al. 1984;
Hayward et al. 2000; Zerba and Sing 1993), examplified
by the present heterogeneity with phenotypic variance
change across age-strata in all lipid traits in both genders,
except for TC in men. The present age-specific prediction
of HDL-C by the g.2059T→C and g.2197C→T SNPs in
Fig. 2a–e (continued)
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females is supported by previous work studying APOE
genotype-phenotype relationships as a function of age
(Zerba et al. 1996, 2000). In this case, both the genetic
variance and the phenotypic variance for HDL-C change
over age-strata; however, the relative change in genetic
variance across age strata (3.5-fold) is several fold larger
than the relative change in phenotypic variance (1.6-fold).
Differences in exposure to environmental factors between
genders (Schnohr et al. 2001) probably contributes to
observed gender differences in genotype effects on means
and variances or to observed gender differences of
genotype-specific correlations between lipids and anthro-
pometric factors (Frikke-Schmidt et al. 2000a; Reilly et al.
1994; Lussier-Cacan et al. 2002).
Furthermore, we find that estimates of phenotypic
variance explained by the g.2059T→C and g.2197C→T
SNPs defining the six traditional APOE genotypes are
approximately twice as high in females than in males in
most age strata. We and others have repeatedly observed
gender-specific patterns of influence of variation in genes
that influence measures of lipid metabolism (Frikke-
Schmidt et al. 2000a, 2000b; Stengård et al. 2002; Reilly
et al. 1991, 1992, 1994; Agerholm-Larsen et al. 2000;
Wittrup et al. 2000). The selected age strata correspond
well with menopausal status in women, a major determi-
nator of plasma lipid levels (Hayward et al. 2000;
Betteridge and Morrell 1998). Several promoters in lipid
genes contain hormone responsive elements (Zannis et al.
2001), and effects of variations in these genes are thus
Fig. 2a–e (continued)
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likely to be modulated by hormonal status, indexed by
gender status, pre- or post-menopausal status, or exoge-
nous hormone treatment status. The gender-specific effects
of the APOE gene observed in our study may be
attributable to differences in environmental contexts, as
suggested by the abolishment of the traditional APOE
genotype effects on HDL-C levels by hormonal replace-
ment treatment in postmenopausal women (Frikke-
Schmidt et al. 2000b). APOE genotype-specific correla-
tions between lipids and body mass index are also highly
dependent on gender, alcohol intake, and smoking (Reilly
et al. 1994; Lussier-Cacan et al. 2002). These specific
findings substantiate that gender- and age-specific esti-
mates of gene effects are pivotal for understanding and
predicting the contribution of genetic variation to inter-
individual phenotypic variation in measures of lipid
metabolism.
Population- and gender-specific effects of additional
APOE promoter SNPs on variation in measures of
lipid metabolism
Our study supports previously reported population-depen-
dent effects of the APOE promoter SNPs. Recently,
Stengård et al. (2002) have presented evidence of context
dependency of variations in APOE promoter SNPs. The
effects are expressed in particular populations and
genders; this is most pronounced in Finnish (North Karelia
sample) and African–Americans (Jackson sample) and less
Fig. 2a–e (continued)
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pronounced in Caucasian–Americans (Rochester sample;
Stengård et al. 2002). The promoter variants are located in
regulatory regions and are thus prone to modulation by
differences in environmental contexts, which are likely to
differ between populations. Unsurprisingly, we have
consequently found different amounts of additional trait
variation predicted by the three APOE promoter SNPs in
the Danish population, a population with different
environmental contexts than the Finnish and African–
American samples. When 1,581 females and 1,449 males
aged 40–59 years from the present study are compared
with a population with similar relative allele frequencies
and age (456 females and 398 males from the Rochester
sample; Stengård et al. 2002), the estimates of phenotypic
variance for TC, HDL-C, and lnTG associated with the
promoter SNPs and with the traditional APOE genotypes
are similar and small in magnitude. The lack of additional
phenotypic variance predicted by the three promoter SNPs
throughout all age and gender strata in the present study is
probably not attributable to a lack of statistical power,
because six out of eight age-gender strata include more
than 700 individuals.
An important context difference between the present
study and many other APOE studies is that lipid values in
The Copenhagen City Heart Study are non-fasting.
However, these lipid values are not postprandial but are
measured at different time points after the last meal, thus
giving a more natural picture of the normal metabolic
cycle. The non-fasting state does not seem to be an
important enhancer or inhibitor of associations of plasma
lipid levels with the APOE g.2059T→C and g.2197C→T
SNPs, because associations are of similar magnitude in
both the fasting (Stengård et al. 2002; Rochester study)
and non-fasting state (present study).
Pairwise LDs
The three pairwise comparisons with highest correlations
(g.−1254T→C/g.2197C→T, g.−1046G→T/g.2059T→C,
g.−1046G→T/g.2197C→T) in the present study have
also been reported in other populations (Fullerton et al.
2000). Although most of the 10 pairwise comparisons in
each gender are highly significant, the magnitude of the
LD is low. Fullerton et al. (2000) have reported that the
high degree of homoplasy and the large number of low
frequency variants explain the low level of LD observed
among site pairs at the APOE locus. Consequently, most
marker SNPs in the APOE gene are probably not useful for
identifying a particular functional variant within the gene.
It is unlikely that the observed weak LD between SNP
pairs affects the estimates of genetic variance presented
here.
Boerwinkle and Sing bias-corrected estimate of
genetic variance
We used the Boerwinkle and Sing bias-corrected estimate
of genetic variance (Boerwinkle and Sing 1986). This bias
correction gives a per observation variance estimate by
adjusting the genotypic sum of squares, from the standard
one-way analysis of variance, by a quantity that increases
with the number of genotypes, providing that the estimate
of the mean square within genotypes (MSW) does not
decrease as additional genotypes are considered. If this
bias correction term is ignored, as is the case when the
often-reported naive standard r2 estimate of genotypic
variance is employed, the genetic variance estimates will
be overestimated (Boerwinkle and Sing 1986). In some
situations, the Boerwinkle and Sing bias-corrected esti-
mator is, however, also biased (Wijsman and Nur 2001).
This bias is small in magnitude in the present study
because of the large sample size and low trait heritability.
In a few cases, we have observed a small decrease in the
estimate of genetic variance when additional sites were
added. In most of these cases, this occurred when
genotypes with large interindividual variances were
added, thus increasing MSW and resulting in a decreased
estimate of the genetic variance.
Estimation of haplotype effects versus genotype
effects
Recent emphasis has been placed on haplotype–phenotype
relations in studies examining multiple SNPs (Klerkx et al.
2003). However, these haplotype–phenotype relations are
estimated with great error. Indeed, it may be impossible to
estimate the effects of a haplotype when there are many
variable sites, because all genotypes that could have the
haplotype do not exist in the sample, or because the
homozygous haplotype is so rare that a reliable estimate of
the average effect is impossible to obtain. To overcome the
problem with rare haplotypes and the huge variation of
their estimated effects, a pooling approach is often used
(Klerkx et al. 2003). The decision regarding which alleles
to pool is arbitrary, and although the number of haplotypes
one has to deal with decreases, this only confounds a
particular haplotype effect with the effects of the
haplotypes with which it is pooled.
In the present study, we wanted to evaluate whether
additional sites improved the prediction of trait variability,
and not which haplotype carries the functional combina-
tion of the DNA variations measured. One can only
capture the linear additive effects with studies of alleles;
the dominance and the epistatic effects that influence the
phenotype reside in the genotypes. Those who seek to
identify haplotype effects are most interested in defining
and understanding allele effects; this can be most
important in plant and animal breeding where gametic
effects are manipulated from generation to generation. In
medicine, however, the primary goal is to identify the
subset of SNPs that defines the set of genotypes that
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predict variation in a particular phenotypic outcome or
discriminate between those who will remain healthy or
those who have or will develop disease.
Conclusion
The pleotropic effects of the APOE gene on measures of
lipid metabolism and in several pathways in the central
nervous system (Mahley et al. 1995; Dietschy and Turley
2001) emphasize the role of APOE as an important
susceptibility gene for risk assessment in common diseases
having a complex multifactorial etiology. Both invariant
and context-dependent inferences concerning the impact
of variation in the APOE gene have emerged from over
20 years of study. Our study of five common polymorph-
isms in the APOE gene in a large European cohort,
representing the population at large, documents that the
pleiotropic effects of variation at the traditional
g.2059T→C and g.2197C→T sites in the fourth exon of
the APOE gene on measures of lipid metabolism manifest
differently in women and men throughout life. Multi-site
genotypes defined by adding SNPs located in the 5′
promoter region to the traditional g.2059T→C and
g.2197C→T SNPs double the estimate of genetic variance
of HDL and APOAI in middle-aged females. The practical
implications of these 5′ SNPs for the clinician need,
however, to be established. The association between an
endpoint phenotype and a predictor should be much
stronger than in the present findings before it is
worthwhile taking it into consideration in risk assessment.
One reservation that should be noted is that our findings
may not apply to other population groups in which other
SNPs (“non-public”) may have significant effects. At
present, the widely accepted research strategy of most
candidate gene studies involves only those polymorphisms
that segregate in all populations or environmental contexts
and assumes that such “public” polymorphisms are
relevant for the prediction of phenotypic variability in
any population or context (Reich et al. 2001). Heteroge-
neity of relative genotype frequencies among populations
and context dependency of genotype effects should not be
ignored, because “non-public” SNPs may have a large
impact in specific populations and contexts. Otherwise, the
quantitative estimates of phenotypic variability attributable
to a candidate gene are not representative of any
population, gender, age, or environmental context.
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